Literature DB >> 9152412

Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages.

M Yamada1, H Niki, M Yamashita, S Mue, K Ohuchi.   

Abstract

Rat peritoneal macrophages were incubated in the presence of cycloheximide or dexamethasone to inhibit the induction of cyclooxygenase (COX)-2 protein synthesis. Thereafter, when the macrophages were incubated in the presence of arachidonic acid, PGE2 production was increased. Western blot analysis demonstrated that COX-2 protein levels were low and were not affected by arachidonic acid treatment. COX-1 protein levels were not affected by arachidonic acid treatment either. The COX-2 inhibitors NS-398 and nimesulide only slightly inhibited PGE2 production, whereas the COX-1/COX-2 inhibitors indomethacin, piroxicam and tenoxicam strongly inhibited PGE2 production. This suggests that under these conditions, PGE2 production is dependent on COX-1. After the macrophages were treated with aspirin to inactivate existing COX-1 and COX-2, however, treatment with 12-0-tetradecanoylphorbol 13-acetate increased PGE2 production. Furthermore, COX-2 protein levels were markedly increased by 12-0-tetradecanoylphorbol 13-acetate treatment, whereas COX-1 protein levels did not change. In this case, both the COX-2 and the COX-1/ COX-2 inhibitors inhibited PGE2 production. This suggest that under these conditions, PGE2 production is dependent on COX-2. Effects of auranofin on COX-1-dependent and COX-2-dependent PGE2 production were examined. We found that auranofin stimulated COX-1-dependent PGE2 production but inhibited COX-2-dependent PGE2 production in a concentration-dependent manner. The latter effect was found to be due to the inhibition of COX-2 protein induction. These findings might explain the mechanism of the antirheumatic and anti-inflammatory activities of auranofin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152412

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer.

Authors:  Garett J Steers; Gloria Y Chen; Brianne R O'Leary; Juan Du; Hannah Van Beek; Joseph J Cullen
Journal:  Antioxidants (Basel)       Date:  2022-05-14

2.  Class A scavenger receptor-mediated macrophage adhesion requires coupling of calcium-independent phospholipase A(2) and 12/15-lipoxygenase to Rac and Cdc42 activation.

Authors:  Dejan M Nikolic; Ming C Gong; John Turk; Steven R Post
Journal:  J Biol Chem       Date:  2007-09-15       Impact factor: 5.157

3.  Impact of maternal dexamethasone on coronary PGE(2) production and prostaglandin-dependent coronary reactivity.

Authors:  Robert D Roghair; Kenneth A Volk; Fred S Lamb; Jeffrey L Segar
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-07-25       Impact factor: 3.619

Review 4.  Aspirin Intolerance: Experimental Models for Bed-to-Bench.

Authors:  Masamichi Yamashita
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

5.  Ginsenoside Rd inhibits the expressions of iNOS and COX-2 by suppressing NF-κB in LPS-stimulated RAW264.7 cells and mouse liver.

Authors:  Dae Hyun Kim; Jae Heun Chung; Ji Sung Yoon; Young Mi Ha; Sungjin Bae; Eun Kyeong Lee; Kyung Jin Jung; Min Sun Kim; You Jung Kim; Mi Kyung Kim; Hae Young Chung
Journal:  J Ginseng Res       Date:  2013-03       Impact factor: 6.060

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.